Podcast appearances and mentions of peter kolchinsky

On this week's episode, Eric Schmidt and Sam Fazeli are joined by special guests Adam Feuerstein and Peter Kolchinsky to discuss the upward movement of the biotech market along with strong drug launches, deals, and net-positive Q1 earnings, all signaling things may be improving. Next, the group notes the FDA is unlikely to undergo significant reorganization and while this stability is reassuring, complacency should be avoided as headwinds persist. Despite the turmoil, the pharmaceutical industry remains resilient, as people prioritize their health and the need for medicine. The conversation shifts back to the new FDA leadership, highlighting Makary and RFK Jr.'s relationship, anti-vaccine rhetoric and the impacts this may have on vaccine trials. The group notes that at conversations at AACR suggest that large pharma is not worried about the FDA changes, while smaller companies have concerns. BridgeBio's successful launch of Attruby was also discussed, highlighted as a positive trend for the industry. The conversation shifts back to vaccine uncertainty and the future of mRNA given the skepticism from healthcare professionals, illustrated by Moderna's potential delays fortheir flu vaccine combo. The episode ends with Adam's optimistic take on biotech's recent turn toward stabilization. *This episode aired on May 2, 2025.

White House plans to slash FDA and NIH risk decimating two agencies at the core of U.S. biomedical innovation. On the latest BioCentury This Week podcast, BioCentury's editors assess draft plans by the Trump administration that seek to halve FDA staff, cut NIH, and reduce overhead payments to academic institutions. The policy addressed in a recent Guest Commentary for BioCentury, “Defending the NIH, the NSF and the foundation of American science,” by the Scleroderma Research Foundation's Luke Evnin, Peter Rubin of No Patient Left Behind, and Ra Capital's Peter Kolchinsky.BioCentury's team also discusses how biotechs are becoming increasingly successful at navigating the obstacles to get precision therapies across the FDA finish line.View full story: https://www.biocentury.com/article/65503400:00 - Introduction00:59 - FDA, NIH & Trump 2.016:26 - Biotechs & Precision MedicineTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

In an era where breakthrough innovations coexist with concerns over drug affordability, Peter Kolchinsky, founder and Managing Partner at healthcare and life sciences investment manager RA Capital, joins us to shed light on the factors and paths forward.Hercules Capital's Janice Bourque engages with Peter on his No Patient Left Behind initiative, a non-profit dedicated to making medicines affordable for everyone in America.Topics Include:Overview of the "No Patient Left Behind" movement and its objectivesExamining communication challenges within the drug industryThe pivotal role of insurance in enabling patient access and affordabilityStrategies to maintain support for innovation amid pricing concernsPotential solutions to bridge the gap between innovation and affordabilityPeter Kolchinsky, PhD is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Peter is an active investor in and board member of publicly- and privately-held companies developing drugs, medical devices, diagnostics, and research tools. He served on the Board of Global Science and Technology for the National Academy of Sciences, is the author of The Entrepreneur's Guide to a Biotech Startup, and frequently writes and speaks on the future of biotechnology innovation. Peter founded and serves as a Director of No Patient Left Behind, a non-profit advocate for healthcare reforms that would make today's medicines affordable to patients and promote the innovation that gives all of us hope for tomorrow. He holds a BA from Cornell University and a PhD in Virology from Harvard University.

In this Vital Health Podcast, Duane Schulthess speaks with Peter Kolchinsky, Managing Partner at RA Capital Management. Peter has authored several critically acclaimed books, including The Great American Drug Deal and The Entrepreneur's Guide to a Biotech Startup. Peter also serves as the Director of No Patient Left Behind, a non-profit organization. Peter outlines that not only are IRA's provisions negotiating small molecules after 9 years a huge challenge, but the continuation of ratcheting up of increasingly hostile regulatory proposals is having a demonstrably negative impact on biopharma investments and innovations. See omnystudio.com/listener for privacy information.

It's clear that we need to fix the way we measure the value of new medicines. Current methods fail to account for the benefits to caregivers, the long-term savings from keeping a job or avoiding the hospital, and the countless scientific discoveries that a new drug can lead to. But there is a solution according to this week's guest, biotech investor Peter Kolchinsky. He talks about his new study that looks at innovative ways to assess the real value of medicine. Peter explains how insurers use cost-effective math to determine what drugs they will and won't cover, and alternative methods that take into account patient and caregiver needs. Plus, Terry and Bob discuss some must-pass healthcare bills for the chronic disease community. New Report: Getting the math right when measuring the value of new medicines Protect Medicare patients' right to get care at home | The Hill  Patients Rising Now Issues Must Pass for Patients List for Congress   Need help? The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands? Our Navigator is an online tool that allows you to search a massive network of health-related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at the Patients Rising Helpline. Have a question or comment about the show, or want to suggest a show topic or share your story as a patient correspondent? Drop us a line: podcast@patientsrising.org The views and opinions expressed herein are those of the guest(s)/ author(s) and do not reflect the official policy or position of Patients Rising, nor do the views and opinions stated on this show reflect the opinions of a guest's current or previous employers.  

Peter Kolchinsky, Managing Partner at RA Capital Management, breaks down a new white paper with Entity rRisk that aims to get the math correct when measuring the value of new medicines; a new report says the HHS Office for Civil Rights wants an update to a 50-year-old law to prevent disability-based discrimination; and Patients Rising Now is supporting The Protecting Health Care for All Patients Act. RA Capital Management U.S. Department of Health and Human Services Webpage: HHS Issues New Proposed Rule to Strengthen Prohibitions Against Discrimination on the Basis of a Disability in Health Care and Human Services Programs Congressional Budget Office Webpage: H.R. 485, Protecting Health Care for All Patients Act of 2023  

So often on the Patients Rising Podcast, we discuss the affordability of healthcare. This week, guest Peter Kolchinsky outlines how thinking of paying for medicines like paying for a house mortgage leads to lower costs for patients, and encourages investment in the cures of tomorrow.  Plus, Terry and Bob look at the latest healthcare headlines, including a promising framework for a PBM bill to address interactions between PBMs and federal health programs. Don't forget to register for the 2023 We the Patients Fly-In! The Great American Drug Deal Senate Finance Committee News Release: Crapo, Wyden Release Legislative Framework to Address PBMs, Prescription Drug Supply Chain   Need help? The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands? Our Navigator is an online tool that allows you to search a massive network of health-related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at the Patients Rising Helpline. Have a question or comment about the show, or want to suggest a show topic or share your story as a patient correspondent? Drop us a line: podcast@patientsrising.org The views and opinions expressed herein are those of the guest(s)/ author(s) and do not reflect the official policy or position of Patients Rising, nor do the views and opinions stated on this show reflect the opinions of a guest's current or previous employers.  

Peter Kolchinsky, Founder and Managing Director of RA Capital Management and Founder of the nonprofit No Patient Left Behind, sits down with Neil to discuss his book “The Great American Drug Deal,” policy fights over pricing, and his organization's efforts to make medicines affordable for all Americans.

In this incredible episode, Mike Rea is joined by Dr. John L. LaMattina. John is the former Senior Vice President of Pfizer Inc and President of Pfizer Global Research & Development. Additionally, he is a senior partner at PureTech Health and an author. He talks about the misconception about Pfizer's profiteering from the pandemic and the drug pricing in America. John also discusses how Gilead's Sovaldi drug for hepatitis C became overpriced in the US and the effects of insurance companies on the drug market. Moreover, he talks about the misinformation about insulin and its pricing, NIH's role in drug discovery research, and the profitability of the pharma industry.Tune in! During this episode, you will learn about;[00:22] Introduction to the show[0:42] Know our guest; Dr. John L. LaMattina, and why he has authored his books[04:58] Misconception about Pfizer's profiteering from the pandemic[08:13] Drug pricing in America[12:35] Gilead's Sovaldi drug for hepatitis C and how it became overpriced in the US more than in other countries [19:57] The cost-effectiveness of PCSK9 in regulating (low-density lipoprotein) LDL cholesterol[21:42] Effect the insurance companies have had on the drug market [26:09] Value of  the ‘me-too' drugs [30:01] The inefficiency of the flu vaccines [33:03] The funding for early-stage mRNA vaccines [34:23] The input of the FDA and CDC in the manufacture of mRNA vaccines [37:46] What is NIH's role in drug discovery research?[38:13] The process and cost of drug discovery; from idea to getting the drug approved[42:39] Misinformation about insulin and its pricing [47:21] Is the value vs. affordability of medicines a reputation challenge or a  commercial challenge for the industry?[51:31] What's the profitability of the pharma industry?[59:48] Recommended reading [01:02:38] How to connect with us Don't forget to Subscribe, Rate, Review, Like, and Share! Resources MentionedBook; Pharma and Profits by John L. LaMattina Book; Devalued and Distrusted by John L. LaMattinaBook; Drug Truths by John L. LaMattinaBook; The Great American Drug Deal by Peter Kolchinsky  Let's Connect!Website: https://www.johnlamattina.com/Twitter: https://twitter.com/john_lamattinaLinkedIn: https://www.linkedin.com/in/john-lamattina-2985a9b/ More Products Follow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ To listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

Biotech investor, scientist and author Peter Kolchinsky, Ph.D. joins the show with our Founder and Chairman, Jim Weiss, to discuss what the passing of the Prescription Drug Pricing Reform bill would mean for our industry.

In this episode, DLA Piper's Jim Greenwood and Geoff Levitt are joined by Peter Kolchinsky, founding Partner and Portfolio Manager at RA Capital, to discuss the importance of – and complications in – balancing biopharmaceutical innovation, industry regulations and prescription drug availability. See omnystudio.com/listener for privacy information.

Joe Selvaggi talks with virologist Dr. Peter Kolchinsky about the explosion of vaccine technologies and innovations brought into the spotlight by the massive investment to fight the pandemic, and dives deeply into the exciting promise of vaccines to combat an ever-widening range of disease.

This week on Hubwonk, host Joe Selvaggi talks with virologist, Dr. Peter Kolchinsky, about the explosion of vaccine technologies and innovations brought into the spotlight by the massive investment to fight the pandemic, and dives deeply into the exciting promise of vaccines to combat an ever-widening range of disease. Guest: Peter Kolchinsky, Ph.D. is a biotechnology […]

Today's guest describes drug development in the American healthcare market with the analogy of mortgages and rents.People would rather pay higher mortgages because they are finite than pay rent indefinitely. Market-based pricing means that drugs will cost more until they become generic, whereas price control means paying rent forever.In this episode, we interview Peter Kolchinsky, Managing Partner at RA Capital Management , LP and author of The Great American Drug Deal, about the state of drug development in the light of current events in policymaking.In this episode, we discuss:The investor's paradox and expecting drugs to failWhy the market, not the government, should steer drug developmentThe mortgage vs. rent analogyWhy insurance is essential to drug developmentHow a trust in healthcare allows global society to functionAs we continue this journey together, we want to hear from you, the listener. Email John@incubatecoalition.org or Ashlyn@incubatecoalition.org what's top of mind, what story you want to hear, or what you find interesting!To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.Listening on a desktop & can't see the links? Just search for Making Medicine in your favorite podcast player.

Biotechnology investor, Peter Kolchinsky, joins the State of Health to talk with Gunnar about drug pricing. The conversation covers the long term view that when drugs go generic without undue delay, the value they provide to society is far greater than the short-run value that cost effectiveness analyses often show, which Peter details in his book, The Great American Drug Deal: A New Prescription for Innovative and Affordable Medicines. Peter also talks about his new non-profit, No Patient Left Behind, of which Gunnar is a part, and why out of pocket costs should be seen as the true barriers between innovative medicines and patients. Peter uses the COVID-19 pandemic as a case study for improving access issues insofar that out of pocket costs were largely eliminated for vaccines. No Patient Left behind is on twitter @NPLB_org and on the web at www.nopatientleftbehind.org Learn more about your ad choices. Visit podcastchoices.com/adchoices

Investing with confidence, and with a conscience – yes, it is possible to do both.In our second interview with scientist-turned-investor Peter Kolchinsky, co-founder and Managing Partner at RA Capital Management, LP and author of The Great American Drug Deal: A New Prescription for Innovative and Affordable Medicines, we discuss his transition into biotech portfolio management, the art of unearthing potential investment opportunities through competitive mapping, and what it means to make a difference through his affiliation with nonprofit No Patient Left Behind. Check out some of his firm's fascinating, detailed landscape maps for COVID-19 diagnostics, therapeutics and vaccines here.Listen to our first interview with Peter Kolchinsky here.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you're hearing?  Be sure to rate and review us!  We want to hear from you!  If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

 Biopharmaceutical innovation requires a hefty investment: A recent study published in The Journal of the American Medical Association (JAMA) reported an average cost of $1.3 billion to bring a new drug to market, from drug discovery through clinical trials to approval. And it is often the biopharma company that comes under fire when cost burden to patients is in question. But affordability of these innovations is not the biopharma industry's cross to bear alone, according to Peter Kolchinsky, co-founder and Managing Partner at RA Capital Management, LP and author of The Great American Drug Deal: A New Prescription for Innovative and Affordable Medicines. In this first of two interviews, Kolchinsky sits down with host Jeff Stewart to discuss the current healthcare landscape and how government, society, the insurance industry and biopharma must work together in order to fulfill what he calls the “biotech social contract” – where patients will be able to afford their treatments and society will continue to reap the benefits of medical innovation. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health. Like what you're hearing?  Be sure to rate and review us!  We want to hear from you!  If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

Join Host Joe Selvaggi and Virologist and Investor Dr. Peter Kolchinsky as they discuss the rapid development, efficacy, and roll out of the newly approved COVID-19 vaccines.

In our latest episode, Peter Kolchinsky, Ph.D., co-founder of RA Capital and published author, and Kush Parmar, M.D., Ph.D., managing partner of 5AM Ventures, join us to discuss a timely topic during a global pandemic: The Promise and Hope of Biotech. This discussion covers:How biotech varies from other sectors and why it's a specialized field;The evolution of the biotech and big pharma ecosystem;Balancing financial acumen and medical knowledge in a highly technical field;Why the NPV model doesn't tell all and how to source investments;The role of biotech in the COVID pandemic;Innovation and building the industry of the future

Steve and Corey speak with Dr. Michael Kauffman, co-founder and CEO of Karyopharm Therapeutics, about cancer and biotech innovation. Michael explains how he and Dr. Sharon Schacham tested her idea regarding nuclear-transport using simulation software on a home laptop, and went on to beat 1000:1 odds to create a billion dollar company. They discuss the relationship between high proprietary drug costs and economic incentives for drug discovery. They also discuss the unique US biotech ecosystem, and why innovation is easier in small (vs. large) companies. Michael explains how Karyopharm is targeting its drug at COVID-induced inflammation to treat people with severe forms of the disease.Resources Transcript Michael Kauffman (Bio) Karyopharm's Publications and Presentations The Great American Drug Deal: A New Prescription for Innovative and Affordable Medicines by Peter Kolchinsky

Steve and Corey speak with Dr. Michael Kauffman, co-founder and CEO of Karyopharm Therapeutics, about cancer and biotech innovation. Michael explains how he and Dr. Sharon Schacham tested her idea regarding nuclear-transport using simulation software on a home laptop, and went on to beat 1000:1 odds to create a billion dollar company. They discuss the relationship between high proprietary drug costs and economic incentives for drug discovery. They also discuss the unique US biotech ecosystem, and why innovation is easier in small (vs. large) companies. Michael explains how Karyopharm is targeting its drug at COVID-induced inflammation to treat people with severe forms of the disease.Resources Transcript Michael Kauffman (Bio) Karyopharm's Publications and Presentations The Great American Drug Deal: A New Prescription for Innovative and Affordable Medicines by Peter Kolchinsky

This week on Hubwonk, Host Joe Selvaggi is joined by Pioneer's Bill Smith, Visiting Fellow in Life Sciences, and Dr. Peter Kolchinsky, Harvard-trained virologist, biotech investor and author of the new book, The Great American Drug Deal, to learn how the SARS-CoV2 works, what a vaccine may look like, and how we might produce it to scale.

As the debate over drug pricing intensifies, biotech investor Peter Kolchinsky is weighing in with a proposed approach to balance access to medicines with the incentive for companies to invest in the development of innovative new therapies. In his new book The Great American Drug Deal, Kolchinsky makes the case for an approach to drug pricing that would ensure that the timely movement of innovative drugs to generic versions while also suggesting mechanisms for cutting the price of therapeutics after patents and exclusivity periods expire when competition fails to arise. We spoke to Kolchinsky about The Great American Drug Deal, his notion of a biotech social contract, and why it's critical that the industry think differently than it has in the past about approaches to reform drug pricing.